239 related articles for article (PubMed ID: 2730960)
1. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.
Colomer R; Ruibal A; Genollá J; Rubio D; Del Campo JM; Bodi R; Salvador L
Breast Cancer Res Treat; 1989 Mar; 13(2):123-33. PubMed ID: 2730960
[TBL] [Abstract][Full Text] [Related]
2. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.
Molina R; Zanón G; Filella X; Moreno F; Jo J; Daniels M; Latre ML; Giménez N; Pahisa J; Velasco M
Breast Cancer Res Treat; 1995; 36(1):41-8. PubMed ID: 7579505
[TBL] [Abstract][Full Text] [Related]
3. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
4. [The value of tumor markers CA 15-3 and CEA in breast cancer].
Buck I; Lindner C; Böge K; Kitschke HJ
Arch Gynecol Obstet; 1989; 245(1-4):674-7. PubMed ID: 2802753
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.
Kandylis K; Vassilomanolakis M; Baziotis N; Papadimitriou A; Tsoussis S; Ferderigou A; Efremidis AP
Ann Oncol; 1990 Nov; 1(6):435-8. PubMed ID: 2083187
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
7. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
[TBL] [Abstract][Full Text] [Related]
8. A new biomarker in monitoring breast cancer: CA 549.
Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
[TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast.
Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Folldi MO; Awwad AH; Nasralla MY; Szymendera JJ
Int J Biol Markers; 1988; 3(3):165-71. PubMed ID: 3230336
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
Safi F; Kuhns V; Beger HG
Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
[TBL] [Abstract][Full Text] [Related]
11. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers in breast cancer: on the diagnostic value of serum determinations in clinical freedom from tumor and manifest disease].
Günczler P; Ogris E; Maca S; Danmayr E
Onkologie; 1989 Oct; 12(5):209-14. PubMed ID: 2685686
[TBL] [Abstract][Full Text] [Related]
13. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
15. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer.
Hall NR; Finan PJ; Stephenson BM; Purves DA; Cooper EH
Br J Cancer; 1994 Sep; 70(3):549-53. PubMed ID: 8080745
[TBL] [Abstract][Full Text] [Related]
16. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
17. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
19. Markers in breast cancer: does CEA add to the detection by CA 15.3?
Delarue JC; Mouriesse H; Dubois F; Friedman S; May-Levin F
Breast Cancer Res Treat; 1988 Jul; 11(3):273-6. PubMed ID: 3167234
[TBL] [Abstract][Full Text] [Related]
20. Serial measurements of Ca antigen in sera from patients with advanced malignant breast disease.
Searle F; Chantler SM; Goodall AB; Adam T; Bagshawe KD; Mitchell HD; Boxer GM; Southall PM
Clin Chim Acta; 1990 Jan; 186(3):351-8. PubMed ID: 2311260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
